$MXCT News

MaxCyte, Inc. (MXCT) Q1 2026 Earnings Call Transcript

MaxCyte (NASDAQ:MXCT) Q1 2026 Results Beat Estimates, Stock Rises on Buyback

MaxCyte Affirms FY2026 Sales Guidance of $30.000M-$32.000M vs $30.829M Est

MaxCyte Q1 EPS $(0.04) Beats $(0.07) Estimate, Sales $9.651M Beat $7.298M Estimate

Craig-Hallum Maintains Buy on MaxCyte, Lowers Price Target to $5

MaxCyte, Inc. (MXCT) Q4 2025 Earnings Call Transcript

MaxCyte Inc (NASDAQ:MXCT) Reports Q4 2025 Revenue Miss and Cautious 2026 Outlook

MaxCyte Sees FY2026 Sales $30.000M-$32.000M vs $38.405M Est

MaxCyte Q4 EPS $(0.09), Inline, Sales $7.300M Miss $9.398M Estimate

MaxCyte Appoints Parmeet Ahuja As CFO

MaxCyte Appoints Parmeet Ahuja As CFO

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results

MaxCyte Reports Q4 Revenue Around $6.7M Vs $9.3M Est, Full-Year Revenue Near $30M Vs $35.41M Est

MaxCyte Inc (MXCT) Q3 2025 Earnings Call Highlights: Strategic Moves Amidst Market Challenges

MaxCyte Announces Planned CFO Transition in 2026

MaxCyte, Inc. (MXCT) Q3 2025 Earnings Call Transcript

MaxCyte CFO Douglas Swirsky To Transition From Role In H1 2026

MaxCyte Affirms FY2025 Sales Guidance of $29.261M-$32.512M vs $36.402M Est

MaxCyte Q3 EPS $(0.12) Misses $(0.11) Estimate, Sales $6.829M Miss $8.370M Estimate

Insights into MaxCyte's Upcoming Earnings